戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ist amodiaquine (AQ) together with l-DOPA or ropinirole.
2 tor VIII protects cells from H2O2 similar to ropinirole.
3 on) and prevented the protection mediated by ropinirole.
4 sonian effects of the D2/D3 receptor agonist ropinirole.
5               At about 5 months post-lesion, ropinirole (0.2 mg/kg, i.p.) was administered daily for
6  oxidative stress and protection provided by ropinirole, a D2 receptor agonist in PC12 cells and prim
7 in the Btbd9 mutant mice were relieved using ropinirole, a dopaminergic agonist widely used for RLS t
8 veal whether their over-expression modulated ropinirole activity.
9 ore drive risky decision-making on-task, and ropinirole acts synergistically with win-paired cues to
10 ith dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levod
11  the role of dopamine agonists, particularly ropinirole and pramipexole, and management of motor and
12 x vivo cFos imaging showed that both chronic ropinirole and the addition of win-paired cues suppresse
13 including dopamine agonists (pramipexole and ropinirole) and alpha2 delta ligands (gabapentin).
14 nt targets for locally perfused pramipexole, ropinirole, and gabapentin, which significantly countera
15 lometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications.
16 g-like" dual acting molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 2413
17 ore appeared to perpetuate risky choice, and ropinirole exaggerated this disconnect in synergy with r
18 chlorperazine) and a lower-affinity agonist (ropinirole) exhibited reduced temporal dissociation betw
19      In contrast, the subtherapeutic dose of ropinirole generated only modest motor effects in lesion
20 o be significantly (one third) slower in the ropinirole group compared with that of the L-DOPA group.
21                               Patients given ropinirole had significantly reduced loss of striatal up
22                   The subtherapeutic dose of ropinirole improved the use of previously akinetic forel
23 upport the use of the subtherapeutic dose of ropinirole in a chronic model of PD.
24                                              Ropinirole increased risky decision-making in rats, but
25                           Early in training, ropinirole increased win-stay behavior after large unlik
26      Network analyses further suggested that ropinirole induced decoupling of the dopaminergic cells
27                                              Ropinirole-induced protection was associated with phosph
28  for Galpha(o), that the agonist activity of ropinirole is biased in favor of Galpha(i1) recruitment,
29 hty-six PD patients were randomized (1:1) to ropinirole or L-DOPA therapy, and (18)F-DOPA PET was per
30  patients taking either the dopamine agonist ropinirole or L-DOPA.
31 e and duloxetine (RR = 1.94); loratadine and ropinirole (RR = 3.21); and promethazine and tegaserod (
32                     cFos imaging showed that ropinirole suppressed activity of midbrain dopamine neur
33                           Here, we show that ropinirole treatment in male rats transiently increased
34                                              Ropinirole treatment was associated with rapid transloca
35 2 and 3 (D2R and D3R) as possible targets of ropinirole, we over-expressed these dopamine receptor ge
36 g analysis of the pEC(50) data revealed that ropinirole (which is not associated with valvulopathy) w
37                                              Ropinirole, which is a non-ergot dopamine agonist deriva